ModPath Chat

ModPath Chat

By Modern PathologyScienceMedicineHealth & FitnessLife Sciences
Download on the App Store

ModPath Chat episodes

  • Kinase Fusion Related Thyroid Cancers

    Dr. Peter Sadow, Director of Head and Neck Pathology at MGH discusses with Modern Pathology Editor Dr. George Netto his recent work defining morphologic correlates of the expanding list of Kinase Fusions driving thyroid cancers. A triage testing algorithm and therapeutic implications are highlighted in the discussion. Study by Chu et al, Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. Modern Pathology 33, 2458-2472, 2020. 

    https://www.nature.com/articles/s41379-020-0638-5  

    17 min
  • Pancreatic Cancer Genetics 2020
    The recent publication of the "Pan-Cancer Atlas" by the Pan-Cancer Analysis of Whole Genomes Consortium provided a great opportunity for Dr. Ralph Hruban and his team to reflect on where we stand in our understanding of the genetics of pancreatic cancer. From germline variants that predispose to the development of the disease, to somatic mutations that are therapeutically targetable, genetics is now providing hope, where there once was no hope, for those diagnosed with pancreatic cancer. Study by Thompson et al, The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Modern Pathology 33, 2544-2563, 2020. https://www.nature.com/articles/s41379-020-0629-6
    21 min
  • ALK rearranged renal cell carcinoma (ALK-RCC)

    The host discusses with Professor Ondrej Hes, from the Charles University in the Czech Republic, his recent multi-institutional study that further defines ALK-RCC as a genetically distinct renal cancer type showing a heterogeneous histomorphology. The authors advocate a routine ALK IHC screening for "unclassifiable RCCs" with heterogeneous features. 


    Study by Kuroda et al, ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Modern Pathology 2020. https://www.nature.com/articles/s41379-020-0578-0.  

    15 min
  • Xanthogranulomatous epithelial tumor

    Dr Netto discusses with Dr. Andrew Folpe a novel tumor of soft tissue and bone with a predilection for young females. The newly discovered lesion is provisionally termed "xanthogranulomatous epithelial tumor". Clues to the diagnosis of this tumor type are presented by Dr. Folpe with a practical guide to navigating the challenging differential diagnosis of epithelial expression in mesenchymal neoplasms.


    Study by Fritchie et al, Xanthogranulomatous epithelial tumor: report of 6 cases of a novel, potentially deceptive lesion with a predilection for young women. Modern Pathology, 33, 1889-1895. 2020. https://www.nature.com/articles/s41379-020-0562-8.

    23 min
  • COVID-19 pulmonary pathology in cross Atlantic pandemic epicenters
    A discussion with Dr. Borczuk of New York Presbyterian Hospital- Weill Cornell Medicine on his team findings in sixty eight COVID-19 autopsies, performed early on during the pandemic, at 3 institutions in heavily hit areas (2 USA, 1 Italy). While a heterogeneous disease, COVID-19 pneumonia displayed consistent features in all three centers. Study by Borczuk et al, COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Modern Pathology, 2020. https://www.nature.com/articles/s41379-020-00661-1.
    20 min
  • Quantitative assessment of residual pancreatic intraductal carcinoma following neoadjuvant chemotherapy
    Modern Pathology Editor in Chief discusses with Laura Wood MD PhD her recent study on quantitative assessment of residual pancreatic intraductal carcinoma following neoadjuvant chemotherapy. The implications of finding that the intraductal component of pancreatic cancer is more resistant to chemotherapy are highlighted. Study by Fujikura et al, Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy. Modern Pathology, 2020. https://www.nature.com/articles/s41379-020-0572-6
    17 min
  • Using "ONEST" algorithm to improve reproducibility of PD-L1 assessment by pathologists

    A conversation with David Rimm, the author of a recent study on Triple negative breast cancer, on using a novel statistical algorithm (ONEST) to improve reproducibility of PD-L1 assessment by pathologists.


    Study by Reisenbichler et al, Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Modern Pathology, 2020. https://www.nature.com/articles/s41379-020-0544-x

    15 min
  • Using “ONEST” algorithm to improve reproducibility of PD-L1 assessment by pathologists

    A conversation with David Rimm, the author of a recent study on Triple negative breast cancer, on using a novel statistical algorithm (ONEST) to improve reproducibility of PD-L1 assessment by pathologists.


    Study by Reisenbichler et al, Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Modern Pathology, 2020. https://www.nature.com/articles/s41379-020-0544-x


    Hosted on Acast. See acast.com/privacy for more information.

    15 min

About ModPath Chat

From the publisher's feed

ModPath Chat is the official podcast of Modern Pathology, the journal of the US and Canadian Academy of Pathology (USCAP). ModPath Chat features interviews with authors, opinion leaders and experts on…